Literature DB >> 1917297

Minimum analogue peptide sets (MAPS) for quantitative structure-activity relationships.

S Hellberg1, L Eriksson, J Jonsson, F Lindgren, M Sjöström, B Skagerberg, S Wold, P Andrews.   

Abstract

The information contents in previously published peptide sets was compared with smaller sets of peptides selected according to statistical designs. It was found that minimum analogue peptide sets (MAPS) constructed by factorial or fractional factorial designs in physiochemical properties contained substantial structure-activity information. Although five to six times smaller than the originally published peptide sets the MAPS resulted in QSAR models able to predict biological activity. The QSARs derived from a MAPS of nine dipeptides, and from a set of 58 dipeptides inhibiting angiotensin converting enzyme were compared and found to be of equal strength. Furthermore, for a set of bitter tasting dipeptides it was found that an incomplete MAPS of 10 dipeptides gave just as good a model as the model based on a set of 48 dipeptides. By comparison other non-designed sets of peptides gave QSARs with poor predictive power. It was also demonstrated how MAPS centered on a lead peptide can be constructed as to specifically explore the physiochemical and biological properties in the vicinity of the lead. It was concluded that small information-rich peptide sets MAPS can be constructed on the basis of statistical designs with principal properties of amino acids as design variables.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1917297     DOI: 10.1111/j.1399-3011.1991.tb00756.x

Source DB:  PubMed          Journal:  Int J Pept Protein Res        ISSN: 0367-8377


  17 in total

1.  Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection.

Authors:  Alexander Golbraikh; Alexander Tropsha
Journal:  J Comput Aided Mol Des       Date:  2002 May-Jun       Impact factor: 3.686

2.  Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection.

Authors:  Alexander Golbraikh; Alexander Tropsha
Journal:  Mol Divers       Date:  2002       Impact factor: 2.943

3.  QSAR study on angiotensin-converting enzyme inhibitor oligopeptides based on a novel set of sequence information descriptors.

Authors:  Xiaoyu Wang; Juan Wang; Yong Lin; Yuan Ding; Yuanqiang Wang; Xiaoming Cheng; Zhihua Lin
Journal:  J Mol Model       Date:  2010-10-13       Impact factor: 1.810

4.  Towards the chemometric dissection of peptide--HLA-A*0201 binding affinity: comparison of local and global QSAR models.

Authors:  Irini A Doytchinova; Valerie Walshe; Persephone Borrow; Darren R Flower
Journal:  J Comput Aided Mol Des       Date:  2005-03       Impact factor: 3.686

5.  Lipophilicity of amino acids.

Authors:  H van de Waterbeemd; H Karajiannis; N El Tayar
Journal:  Amino Acids       Date:  1994-06       Impact factor: 3.520

6.  Extensions to amino acid description.

Authors:  Johan Gottfries; Lennart Eriksson
Journal:  Mol Divers       Date:  2009-11-25       Impact factor: 2.943

7.  Quantitative sequence-activity models (QSAM)--tools for sequence design.

Authors:  J Jonsson; T Norberg; L Carlsson; C Gustafsson; S Wold
Journal:  Nucleic Acids Res       Date:  1993-02-11       Impact factor: 16.971

8.  Modeling the QSAR of ACE-Inhibitory Peptides with ANN and Its Applied Illustration.

Authors:  Ronghai He; Haile Ma; Weirui Zhao; Wenjuan Qu; Jiewen Zhao; Lin Luo; Wenxue Zhu
Journal:  Int J Pept       Date:  2011-06-09

9.  An index for characterization of natural and non-natural amino acids for peptidomimetics.

Authors:  Guizhao Liang; Yonglan Liu; Bozhi Shi; Jun Zhao; Jie Zheng
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

10.  QSBR study of bitter taste of peptides: application of GA-PLS in combination with MLR, SVM, and ANN approaches.

Authors:  Somaieh Soltani; Hossein Haghaei; Ali Shayanfar; Javad Vallipour; Karim Asadpour Zeynali; Abolghasem Jouyban
Journal:  Biomed Res Int       Date:  2013-11-25       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.